Truist lowered the firm’s price target on Perspective Therapeutics (CATX) to $10 from $21 and keeps a Buy rating on the shares. Based on its discussions with the management, the firm has adjusted its model’s launch curve timelines for the company’s lead assets to reflect the pace of the dose escalation trials for two clinical programs, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Positive Outlook for Perspective Therapeutics Despite Wider Net Loss, Supported by Strong Cash Position and Upcoming Catalysts
- Perspective Therapeutics management to meet with Oppenheimer
- Promising Outlook for Perspective Therapeutics: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position
- Perspective Therapeutics Reports 2024 Earnings and Clinical Progress
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025